Written by students who passed Immediately available after payment Read online or as PDF Wrong document? Swap it for free 4.6 TrustPilot
logo-home
Document preview thumbnail
Preview 4 out of 37 pages
Exam (elaborations)

NR 546 Midterm Exam / NR546 Psychopharmacology for the Psychiatric-Mental Health Nurse Practitioner Midterm Exam | Chamberlain University (Latest 2026/2027/2028 Testing Cycle Guide with Answers & Rationales)

Document preview thumbnail
Preview 4 out of 37 pages

Pass NR546 Psychopharmacology for the Psychiatric-Mental Health Nurse Practitioner Midterm Exam at Chamberlain University with this newly released complete guide for the 2026/2028 testing cycle featuring 75 verified questions, answers, and expert rationales – 100% correct, graded A+, guaranteed pass. This comprehensive resource covers advanced psychopharmacology: pharmacokinetics (absorption, distribution, metabolism – CYP450, first-pass effect, excretion), pharmacodynamics (receptor theory, agonists/antagonists, potency, efficacy, therapeutic index, dose-response curves), antidepressants (SSRIs – fluoxetine, sertraline; SNRIs – venlafaxine, duloxetine; TCAs – amitriptyline; MAOIs – phenelzine; mechanisms, side effects, drug interactions, serotonin syndrome, discontinuation syndrome), antipsychotics (first-generation – haloperidol (EPS, tardive dyskinesia, NMS); second-generation – risperidone, olanzapine, quetiapine, clozapine (metabolic syndrome, agranulocytosis monitoring); indications, side effect profiles, monitoring), mood stabilizers (lithium – therapeutic range 0.6-1.2 mEq/L, toxicity signs – tremor, ataxia, nausea, polyuria, avoid NSAIDs; valproate – hepatotoxicity, pancreatitis, teratogenic; lamotrigine – Stevens-Johnson syndrome; carbamazepine – blood dyscrasias), anxiolytics (benzodiazepines – lorazepam, alprazolam – dependence, withdrawal, sedation; buspirone – no dependence, delayed onset; hydroxyzine; gabapentin), stimulants (methylphenidate, amphetamines – ADHD, side effects – insomnia, appetite suppression, growth suppression), medications for substance use disorders (naltrexone – opioid/alcohol use disorder; buprenorphine/naloxone – opioid use disorder; disulfiram – alcohol use disorder, disulfiram reaction; acamprosate – alcohol use disorder; methadone – opioid use disorder), and special populations (pregnancy/lactation, pediatric, geriatric). Each expert rationale explains mechanisms, side effects, drug interactions, monitoring parameters, and clinical decision-making. Get instant access now and start studying today.

Content preview

NR546 /NR 546: Midterm Exam
-Psychopharmacology for the Psychiatric-Mental
Health Nurse Practitioner |
-Advanced Psychopharmacology
2026| 2027| 2028 Testing Cycle | Complete Guide
75 Questions With Answers & Expert Rationales
Guaranteed Pass | Graded A+ | Chamberlain


Q1: A 34-year-old patient with schizophrenia is prescribed an atypical antipsychotic. The
medication works primarily through antagonism at which receptor to reduce positive symptoms?

A. 5-HT1A

B. D2

C. GABA-A

D. NMDA

Correct Answer: B

Rationale: Correct because D2 receptor antagonism in the mesolimbic pathway is the primary
mechanism by which antipsychotics reduce positive symptoms such as hallucinations and
delusions. The mesolimbic pathway is hyperdopaminergic in schizophrenia, and blocking D2
receptors modulates this excess dopamine transmission. While 5-HT2A antagonism characterizes
atypical antipsychotics, the reduction of positive symptoms specifically requires D2 receptor
blockade.

,Q2: A 45-year-old patient on haloperidol for schizophrenia starts bupropion for smoking
cessation. Two weeks later, the patient develops severe rigidity, fever, and confusion. Which
metabolic interaction explains this presentation?

A. Bupropion inhibits CYP3A4, increasing haloperidol levels

B. Bupropion induces CYP2D6, decreasing haloperidol levels

C. Bupropion inhibits CYP1A2, increasing haloperidol levels

D. Bupropion inhibits CYP2D6, increasing haloperidol levels

Correct Answer: D
Rationale: Correct because bupropion is a potent CYP2D6 inhibitor, and haloperidol is a major
CYP2D6 substrate; this interaction significantly elevates haloperidol plasma concentrations. The
elevated haloperidol levels cause severe dopamine blockade, precipitating neuroleptic malignant
syndrome characterized by fever, rigidity, and altered mental status. CYP3A4 and CYP1A2 are
not the primary metabolic pathways involved in this specific drug-drug interaction.



Q3: A 28-year-old woman with major depressive disorder reports decreased libido and
anorgasmia since starting sertraline four weeks ago. Which neurotransmitter mechanism is
responsible for these adverse effects?

A. Increased synaptic serotonin via SERT inhibition

B. Increased synaptic norepinephrine via NET inhibition

C. Increased synaptic dopamine via DAT inhibition

D. Increased GABA activity via GABA-A modulation

Correct Answer: A

Rationale: Correct because SSRIs such as sertraline inhibit the serotonin transporter (SERT),
leading to increased synaptic serotonin levels that suppress sexual function through 5-HT2A
receptor activation in the spinal cord and hypothalamus. Serotonergic excess interferes with
dopamine-mediated sexual arousal and orgasm pathways, producing decreased libido and
anorgasmia. Norepinephrine and GABA mechanisms are not primarily responsible for SSRI-
induced sexual dysfunction.

,Q4: A 52-year-old patient on clozapine presents with fever, sore throat, and mouth ulcers.
Laboratory studies reveal an absolute neutrophil count of 850. What is the appropriate clinical
action?

A. Continue clozapine and monitor weekly

B. Stop clozapine immediately and monitor ANC

C. Reduce clozapine dose by 50% and recheck in one week

D. Start granulocyte colony-stimulating factor and continue clozapine

Correct Answer: B
Rationale: Correct because an ANC below 1000 mandates immediate discontinuation of
clozapine per the REMS program guidelines due to the risk of life-threatening agranulocytosis.
The patient must be monitored closely with frequent CBC differentials until the ANC recovers
above 1500, at which point rechallenging may be considered. Continuing or reducing the dose
places the patient at unacceptable risk for sepsis and infectious complications.



Q5: A researcher is studying a novel antidepressant that increases cyclic AMP (cAMP) through
activation of adenylyl cyclase. Which G-protein subtype mediates this effect?

A. Gi

B. Gq

C. Gs

D. Go

Correct Answer: C

Rationale: Correct because Gs proteins stimulate adenylyl cyclase, catalyzing the conversion of
ATP to cyclic AMP and activating downstream protein kinase A signaling. This second
messenger cascade is critical for antidepressant-induced neuroplasticity involving BDNF and
CREB phosphorylation. Gi proteins inhibit adenylyl cyclase, while Gq proteins activate
phospholipase C to generate IP3 and DAG.

, Q6: An 82-year-old patient with insomnia is prescribed a benzodiazepine. According to the
Beers Criteria, which agent is preferred in this geriatric population?

A. Diazepam

B. Lorazepam

C. Chlordiazepoxide

D. Clonazepam

Correct Answer: B

Rationale: Correct because lorazepam is a short-acting benzodiazepine with a relatively
straightforward metabolic pathway that avoids excessive accumulation in elderly patients with
reduced hepatic function. The Beers Criteria explicitly warn against long-acting agents such as
diazepam and chlordiazepoxide due to prolonged half-lives, increased fall risk, cognitive
impairment, and sedation in geriatric patients. Clonazepam, while useful for seizure disorders,
carries intermediate duration risks that make lorazepam preferable for acute anxiety or insomnia
in older adults.



Q7: A 16-year-old adolescent with major depressive disorder is started on fluoxetine. What is the
most critical monitoring requirement during the first two months of treatment?

A. Close observation for suicidal ideation and behavior

B. Weekly fasting glucose monitoring

C. Monthly liver function testing

D. Baseline and quarterly AIMS assessment

Correct Answer: A

Rationale: Correct because all antidepressants carry an FDA Black Box Warning for increased
suicidal ideation and behavior in children, adolescents, and young adults under 24 years of age
during initial treatment and dose adjustments. Close clinical observation, including weekly visits
and caregiver education, is mandatory to detect emergent suicidal thoughts. Fasting glucose, liver
function tests, and AIMS assessments are not standard initial monitoring requirements for
fluoxetine in adolescents.

Document information

Uploaded on
September 1, 2026
Number of pages
37
Written in
2026/2027
Type
Exam (elaborations)
Contains
Questions & answers
$13.50

Wrong document? Swap it for free Within 14 days of purchase and before downloading, you can choose a different document. You can simply spend the amount again.
Written by students who passed
Immediately available after payment
Read online or as PDF

Seller avatar
Reputation scores are based on the amount of documents a seller has sold for a fee and the reviews they have received for those documents. There are three levels: Bronze, Silver and Gold. The better the reputation, the more your can rely on the quality of the sellers work.
TutorRicks
3.6
(52)
Sold
380
Followers
51
Items
2930
Last sold
1 day ago




Why students choose Stuvia

Created by fellow students, verified by reviews

Quality you can trust: written by students who passed their tests and reviewed by others who've used these notes.

Didn't get what you expected? Choose another document

No worries! You can instantly pick a different document that better fits what you're looking for.

Pay as you like, start learning right away

No subscription, no commitments. Pay the way you're used to via credit card and download your PDF document instantly.

Student with book image

“Bought, downloaded, and aced it. It really can be that simple.”

Alisha Student

Working on your references?

Create accurate citations in APA, MLA and Harvard with our free citation generator.

Working on your references?

Frequently asked questions